- Home
- PDCO vs MYGN Comparison
PDCO vs MYGN Comparison
Compare PDCO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDCO
- MYGN
- Stock Information
- Founded
- PDCO 1877
- MYGN 1991
- Country
- PDCO United States
- MYGN United States
- Employees
- PDCO N/A
- MYGN N/A
- Industry
- PDCO Medical Specialities
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PDCO Health Care
- MYGN Health Care
- Exchange
- PDCO Nasdaq
- MYGN Nasdaq
- Market Cap
- PDCO 2.7B
- MYGN 2.0B
- IPO Year
- PDCO 1992
- MYGN 1995
- Fundamental
- Price
- PDCO $30.82
- MYGN $13.50
- Analyst Decision
- PDCO Hold
- MYGN Hold
- Analyst Count
- PDCO 7
- MYGN 11
- Target Price
- PDCO $27.10
- MYGN $24.27
- AVG Volume (30 Days)
- PDCO 2.0M
- MYGN 1.1M
- Earning Date
- PDCO 02-26-2025
- MYGN 02-25-2025
- Dividend Yield
- PDCO 3.37%
- MYGN N/A
- EPS Growth
- PDCO N/A
- MYGN N/A
- EPS
- PDCO 1.72
- MYGN N/A
- Revenue
- PDCO $6,554,872,000.00
- MYGN $823,600,000.00
- Revenue This Year
- PDCO $2.81
- MYGN $13.82
- Revenue Next Year
- PDCO $2.87
- MYGN $4.59
- P/E Ratio
- PDCO $17.87
- MYGN N/A
- Revenue Growth
- PDCO 0.05
- MYGN 12.15
- 52 Week Low
- PDCO $19.45
- MYGN $12.87
- 52 Week High
- PDCO $31.79
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- PDCO 83.23
- MYGN 32.61
- Support Level
- PDCO $30.83
- MYGN $13.04
- Resistance Level
- PDCO $30.94
- MYGN $13.77
- Average True Range (ATR)
- PDCO 0.16
- MYGN 0.60
- MACD
- PDCO -0.14
- MYGN 0.14
- Stochastic Oscillator
- PDCO 7.81
- MYGN 24.51
About PDCO Patterson Companies Inc.
Patterson Companies Inc is a dental distributor and wholesaler of consumable products and equipment operating through two business segments, Patterson Dental, and Patterson Animal Health. The company's segment includes Dental, Animal Health, and Corporate. It generates maximum revenue from the Animal Health segment. Geographically, it derives its revenue from the United States, the United Kingdom, and Canada. The firm derives almost all of its revenue from the United States.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.